Biogen And The Progress In Multiple Sclerosis Treatment [View article]
To: Westcoaster Thank you for your comments. Dr Zamboni's idea has not been proven yet. In 2012 the FDA issued a warning, which says, among other things, the following:
"The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called “liberation therapy” or the “liberation procedure” to treat chronic cerebrospinal venous insufficiency (CCSVI). The FDA believes that using these medical devices in CCSVI treatment procedures poses a risk to patients because: There is no clear diagnostic evidence that CCSVI exists as a distinct clinical disorder or is linked to MS. Venous stenoses seen on imaging tests may be normal variants that do not cause any symptoms or disease, since they are sometimes seen in healthy people. The safety and effectiveness of using balloon angioplasty devices or stents in the internal jugular or azygos veins have not been established for any clinical condition; nor has the FDA approved the use of these devices in these veins. There is no clear scientific evidence that the treatment of internal jugular or azygos venous stenosis is safe in MS patients, impacts the symptoms of MS, changes the overall course of MS or improves the quality of life for MS patients. It is possible that stent placement can worsen any venous narrowing. This is because further narrowing has been shown to sometimes occur within stents placed in veins, due to the body’s response to the implant. The FDA encourages research to evaluate the relationship between CCSVI and MS and to characterize the safety and effectiveness of treatment procedures. Rigorously conducted, properly targeted research can provide a more complete understanding of the existence of CCSVI and any relationship between CCSVI and MS, which will help people with the disease and their clinicians make the best treatment decisions."
How Big A Dividend Will Abbott Pay After It Splits? [View article]
numbercrucher45 and Captain Tingles:
1. The dividend figures are estimates, subject to, as clearly stated and sourced in the article, to the the approval of the respective Boards in January. They were given by Thomas C. Freyman - Chief Financial Officer and Executive Vice President of Finance of Abbott
2. At the same earnings conference John B. Thomas - Vice President of Investor Relations & Public Affairs stated: "A few weeks prior to separation, we'll issue a news release describing the special dividend distribution of AbbVie stock, including the distribution ratio and the record date. We expect that when-issued trading of both company stocks to begin in mid-December, with regular rate trading of both companies to begin on January 2 on the New York Stock Exchange."
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy [View article]
To: Tad R As a matter of rule you should not rely in your daily trading decisions on SA articles. These articles provide something more important than daily tips: a review of the science behind the projects and a review of the overall financial picture. A company like Sarepta without an approved drug for sale to the public is a highly speculative investment to begin with. By the way, at this writing the share price is still above both the 50 and 200 day simple moving averages, and if there is no change in the substance, that is the medicine works as claimed, in my opinion this is a very good long term investment. But not for nervous investors.
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy [View article]
Harrywins: This is a horrible disease, which has been a subject of major and continuous fundraising for decades ( Jerry Lewis for example) This is the first time that two companies come up with a disease modifying drug based on a similar scientific concept (exon-skipping). It is not a cure, as stated in the article, but it seems to be a progress. If you think the science behind this is phony, you should write an article laying out your arguments. If you have no scientific arguments, only have problem with the high price of the stock, that's another matter. Any time when a real solution appears for an unsolvable problem, the value of the company behind it goes sky high, for a while, and justifiably so.
Celgene Moves Fast And Early In Expanding Its Pipeline [View article]
biothoughts: Thanks for your kind comment. Notice however that many if not most of the investments were made in very early stage developments. Also notice the ratio of current Revlimid sales to everything else.In biotech, like in life, there is no guarantee for success.
Regeneron's Blockbuster Drug Eylea And Its Potential Competitors [View article]
astorer:
It is a great idea, if it works. I wrote about it myself: http://seekingalpha.co... The trouble is that it is a small company, a revolutionary idea and as such, it probably will take a long time to get somewhere even if it does work.
Regeneron's Blockbuster Drug Eylea And Its Potential Competitors [View article]
toosmarttofail: In an article, http://bit.ly/11Fpl5g Ron Adelman, MD, at Yale University, gives some perspective on Does Surgery Have A Future in Retina Care?
“For AMD, we used to do a number of surgeries, including vitrectomy and removal of subretinal choroidal neovascular membrane,” he says. “Some people used to do other surgeries, such as macular translocation. Those are rarely being done now. There was a time that we did four of those macular degeneration surgeries in one day. Now, I haven’t done any in the last two years because the anti-VEGF treatment is so effective."
Pfizer's Direct-To-Consumer Campaigns: A Model For The Future? [View article]
hirokon: CORRECTION You are right. Pfizer bought a different drugmaker, Wyeth, in 2009 and acquired products including Advil, Caltrate, Centrum vitamins, ChapStick and Robitussin.
Pfizer didn't acquire the Dr. Scholl's foot care and Coppertone sun care product lines, which are now owned by rival Merck & Co. Sorry about the error and thank you for the correction.
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy [View article]
To: themicrokid The source of the section you are questioning is a speech given by Sarepta CEO Chris Garabedian a few days ago, on April 11 at the World Orphan Drug Congress USA, entitled "Sarepta Wants to Change the Way We Do Business with the FDA " where, I believe, he tried to summarize for his audience what happened at the trial and why and recommended changes in the way the FDA handles these very rare diseases. Please read it if you have time. http://bit.ly/113ncfe
Agilent And The Boom In Companion Diagnostics [View article]
To Chubby Lipshitz: On March 07, 2013 on an analyst day event, Ronald S. Nersesian - President and Chief Operating Officer said:
"This year, with the acquisition of Dako, our recurring revenue is up to 30% from approximately 25% just a year ago. And as you can see, we're seeing this type of recurring revenue in all groups and that can be anything from chemistries, reagents, supplies, we see software updates that are also included and service & support. So we continue to expand this space to try to limit our volatility. We play in certain markets, we differentiate in those markets and we'll continue to be there, but we want to make sure that over time, that this is a growing percentage of our portfolio. In addition, we sell software that is not included in recurring revenue that is about $300 million per year. And those are software packages that get added to different product to get new capabilities."
How Big A Dividend Will Abbott Pay After It Splits? [View article]
The dividend is 14 cents from Abbott and 40 cents from AbbVie. Abbott said it is an increase of nearly 6 percent over Abbott's quarterly cash dividend.
How Big A Dividend Will Abbott Pay After It Splits? [View article]
UPDATE: In January 2013 Abbvie declared the Company's first quarterly cash dividend of $0.40 per share. The cash dividend is payable Feb. 15, 2013 to stockholders of record at the close of business on Jan. 15, 2013.
Abbott Laboratories declared a quarterly dividend of $0.54 per share, or $2.16 annualized. This is a 6% increase from the prior dividend of $0.51.
The dividend will be payable on February 15, 2013, to stockholders of record on January 15, 2013, with an ex-dividend date of January 11, 2013.
Biogen And The Progress In Multiple Sclerosis Treatment [View article]
Thank you for your comments.
Dr Zamboni's idea has not been proven yet. In 2012 the FDA issued a warning, which says, among other things, the following:
"The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called “liberation therapy” or the “liberation procedure” to treat chronic cerebrospinal venous insufficiency (CCSVI).
The FDA believes that using these medical devices in CCSVI treatment procedures poses a risk to patients because:
There is no clear diagnostic evidence that CCSVI exists as a distinct clinical disorder or is linked to MS.
Venous stenoses seen on imaging tests may be normal variants that do not cause any symptoms or disease, since they are sometimes seen in healthy people.
The safety and effectiveness of using balloon angioplasty devices or stents in the internal jugular or azygos veins have not been established for any clinical condition; nor has the FDA approved the use of these devices in these veins.
There is no clear scientific evidence that the treatment of internal jugular or azygos venous stenosis is safe in MS patients, impacts the symptoms of MS, changes the overall course of MS or improves the quality of life for MS patients.
It is possible that stent placement can worsen any venous narrowing. This is because further narrowing has been shown to sometimes occur within stents placed in veins, due to the body’s response to the implant.
The FDA encourages research to evaluate the relationship between CCSVI and MS and to characterize the safety and effectiveness of treatment procedures. Rigorously conducted, properly targeted research can provide a more complete understanding of the existence of CCSVI and any relationship between CCSVI and MS, which will help people with the disease and their clinicians make the best treatment decisions."
How Big A Dividend Will Abbott Pay After It Splits? [View article]
1. The dividend figures are estimates, subject to, as clearly stated and sourced in the article, to the the approval of the respective Boards in January.
They were given by Thomas C. Freyman - Chief Financial Officer and Executive Vice President of Finance of Abbott
2. At the same earnings conference John B. Thomas - Vice President of Investor Relations & Public Affairs stated:
"A few weeks prior to separation, we'll issue a news release describing the special dividend distribution of AbbVie stock, including the distribution ratio and the record date. We expect that when-issued trading of both company stocks to begin in mid-December, with regular rate trading of both companies to begin on January 2 on the New York Stock Exchange."
Thank you for your interest anyhow. P.G.
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy [View article]
As a matter of rule you should not rely in your daily trading decisions on SA articles. These articles provide something more important than daily tips: a review of the science behind the projects and a review of the overall financial picture.
A company like Sarepta without an approved drug for sale to the public is a highly speculative investment to begin with.
By the way, at this writing the share price is still above both the 50 and 200 day simple moving averages, and if there is no change in the substance, that is the medicine works as claimed, in my opinion this is a very good long term investment. But not for nervous investors.
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy [View article]
This is a horrible disease, which has been a subject of major and continuous fundraising for decades ( Jerry Lewis for example)
This is the first time that two companies come up with a disease modifying drug based on a similar scientific concept (exon-skipping). It is not a cure, as stated in the article, but it seems to be a progress.
If you think the science behind this is phony, you should write an article laying out your arguments. If you have no scientific arguments, only have problem with the high price of the stock, that's another matter.
Any time when a real solution appears for an unsolvable problem, the value of the company behind it goes sky high, for a while, and justifiably so.
Celgene Moves Fast And Early In Expanding Its Pipeline [View article]
Thanks for your kind comment. Notice however that many if not most of the investments were made in very early stage developments. Also notice the ratio of current Revlimid sales to everything else.In biotech, like in life, there is no guarantee for success.
Regeneron's Blockbuster Drug Eylea And Its Potential Competitors [View article]
It is a great idea, if it works. I wrote about it myself:
http://seekingalpha.co...
The trouble is that it is a small company, a revolutionary idea and as such, it probably will take a long time to get somewhere even if it does work.
Regeneron's Blockbuster Drug Eylea And Its Potential Competitors [View article]
In an article,
http://bit.ly/11Fpl5g
Ron Adelman, MD, at Yale University, gives some perspective on Does Surgery Have A Future in Retina Care?
“For AMD, we used to do a number of surgeries, including vitrectomy and removal of subretinal choroidal neovascular membrane,” he says. “Some people used to do other surgeries, such as macular translocation. Those are rarely being done now. There was a time that we did four of those macular degeneration surgeries in one day. Now, I haven’t done any in the last two years because the anti-VEGF treatment is so effective."
Regeneron's Blockbuster Drug Eylea And Its Potential Competitors [View article]
You are right, Isonep is a candidate, along with so many others.
Regeneron's Blockbuster Drug Eylea And Its Potential Competitors [View article]
For Optina please read this:
http://bit.ly/198445H
Pfizer's Direct-To-Consumer Campaigns: A Model For The Future? [View article]
CORRECTION
You are right. Pfizer bought a different drugmaker, Wyeth, in 2009 and acquired products including Advil, Caltrate, Centrum vitamins, ChapStick and Robitussin.
Pfizer didn't acquire the Dr. Scholl's foot care and Coppertone sun care product lines, which are now owned by rival Merck & Co.
Sorry about the error and thank you for the correction.
Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy [View article]
The source of the section you are questioning is a speech given by Sarepta CEO Chris Garabedian a few days ago, on April 11 at the World Orphan Drug Congress USA, entitled "Sarepta Wants to Change the Way We Do Business with the FDA " where, I believe, he tried to summarize for his audience what happened at the trial and why and recommended changes in the way the FDA handles these very rare diseases. Please read it if you have time.
http://bit.ly/113ncfe
Abbott Laboratories' Golden Goose: The Nutrition Business [View article]
You are right, Mead Johnson was split off from Bristol Myers Squibb. Thank you for the correction.
Agilent And The Boom In Companion Diagnostics [View article]
On March 07, 2013 on an analyst day event, Ronald S. Nersesian - President and Chief Operating Officer said:
"This year, with the acquisition of Dako, our recurring revenue is up to 30% from approximately 25% just a year ago. And as you can see, we're seeing this type of recurring revenue in all groups and that can be anything from chemistries, reagents, supplies, we see software updates that are also included and service & support. So we continue to expand this space to try to limit our volatility.
We play in certain markets, we differentiate in those markets and we'll continue to be there, but we want to make sure that over time, that this is a growing percentage of our portfolio. In addition, we sell software that is not included in recurring revenue that is about $300 million per year. And those are software packages that get added to different product to get new capabilities."
How Big A Dividend Will Abbott Pay After It Splits? [View article]
How Big A Dividend Will Abbott Pay After It Splits? [View article]
In January 2013 Abbvie declared the Company's first quarterly cash dividend of $0.40 per share.
The cash dividend is payable Feb. 15, 2013 to stockholders of record at the close of business on Jan. 15, 2013.
Abbott Laboratories declared a quarterly dividend of $0.54 per share, or $2.16 annualized. This is a 6% increase from the prior dividend of $0.51.
The dividend will be payable on February 15, 2013, to stockholders of record on January 15, 2013, with an ex-dividend date of January 11, 2013.
The annual yield on the dividend is 3.3 percent.